Nicolas Granbom

SentoClone AB is a Swedish scientific research company developing SentoClone® - a patented method where the immune defense system is activated and strengthened to combat cancer. SentoClone is registered with the European Medicines Ageny, EMEA, as an SME (small and medium sized enterprises). SentoClone AB is a member of the IML, The Swedish Association for small and medium-sized companies active in R&D. SentoClone AB is owned by a number of venture capital firms, among them Stena Adactum AB, Sahltech i Göteborg AB and T-bolaget AB, together with founders Ola Winqvist and Magnus Thörn.